Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Optimal paricalcitol starting dose for parathyroid hormone suppression in secondary hyperparathyroidism

Nature Clinical Practice Nephrology volume 3, pages 12–13 (2007)Cite this article

boxed-textMitsopoulos E et al. (2006) Initial dosing of paricalcitol based on PTH levels in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 48: 114–121

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Block GA et al. (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208–2218

    Article  CAS  Google Scholar 

  2. National Kidney Foundation (2003) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42 (Suppl 3): S1–S201

  3. Teng M et al. (2005) Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 16: 1115–1125

    Article  CAS  Google Scholar 

  4. Martin KJ et al. (2001) Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized study. Am J Kidney Dis 38 (Suppl 5): S57–S63

    Article  CAS  Google Scholar 

  5. Block GA et al. (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350: 1516–1525

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Chloë Harman, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. University of Rochester School of Medicine and Dentistry, University of Rochester Medical Center, 601 Elmwood Avenue, Box 675, Rochester, NY 14642, USA david_bushinsky@urmc.rochester.edu

Authors and Affiliations

  1. and Chief of the Nephrology Division, DA Bushinsky is Professor of Medicine and of Pharmacology and Physiology, at the University of Rochester School of Medicine, Rochester, NY, USA.,

    David A Bushinsky

Authors
  1. David A Bushinsky
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author has received grant support from the National Institutes of Health, the Renal Research Institute, Genzyme, Ilypsa and Amgen. He has been a member of advisory boards for Ilypsa, Amgen and Shire, and has been on speakers' bureaux for Amgen, Shire, Genzyme and the France Foundation. He owns stock in Amgen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bushinsky, D. Optimal paricalcitol starting dose for parathyroid hormone suppression in secondary hyperparathyroidism. Nat Rev Nephrol 3, 12–13 (2007). https://doi.org/10.1038/ncpneph0363

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneph0363

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing